Cardium Therapeutics (CXM) Enters Into Cross-Strategic Equity Investment Partnership with SourceOne Global Partners

Cardium Therapeutics (NYSE: CXM) today announced that it has entered into a cross-strategic investment agreement with SourceOne Global Partners, a leading supplier of exclusive science-based ingredients and proprietary formulas to the nutritional supplement and related functional food & beverage industries. The Cardium and SourceOne agreement provides for the joint development and commercialization of customized nutritional supplements, as well as pharmaceuticals and medical foods based on SourceOne's branded ingredients that include specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, Ubiquinol-QH, TocoSource Palm Tocotrienols, and VESIsorb.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Gap Inc. names Michael Francis as Old Navy CEO effective November
• Evernorth's SEC filing clears path for Nasdaq listing via SPAC deal
• Truist names Harold Ford Jr. as Wholesale Banking vice chair